Metabolic & GLP-1
Human RCT (post hoc)
Semaglutide slowed blood-based aging clocks in a post hoc trial analysis
Source: Nature Communications
What the study found
Researchers re-analyzed blood DNA methylation from a 32-week placebo-controlled trial of semaglutide in 84 adults with HIV-associated fat redistribution. Several aging clocks moved in the younger direction with semaglutide, including PhenoAge and a roughly 9% slower DunedinPACE pace of aging.
Why it matters for healthspan
This is some of the first randomized-trial evidence linking a GLP-1 drug to measures of biological aging. The authors flag the limits: aging clocks were not a planned outcome, the cohort was small and HIV-specific, follow-up was short, and clock changes are not the same as proven health gains.
Evidence level
Human RCT (post hoc) · Metabolic & GLP-1
Source
Corley MJ, Dwaraka V, Pang APS, et al. Nat Commun. 2026;17. doi:10.1038/s41467-026-72861-3
Educational summary curated by Farhan Tahir, MD, FACR. Not individual medical advice.
Primary source
Corley MJ, Dwaraka V, Pang APS, et al. Nat Commun. 2026;17. doi:10.1038/s41467-026-72861-3